Please login to the form below

Not currently logged in
Email:
Password:

market data

This page shows the latest market data news and features for those working in and with pharma, biotech and healthcare.

Novartis’ heart failure drug Entresto proves superior to enalapril

Novartis’ heart failure drug Entresto proves superior to enalapril

Novartis has released new data for its heart failure treatment Entresto which could help convince doctors and payers of the drug's value. ... The latest market data from Q3 showed the drug achieved $271m compared to the same period last year, and putting

Latest news

  • Roche and AbbVie prepare to move Venclexta into first-line CLL Roche and AbbVie prepare to move Venclexta into first-line CLL

    Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo. ... The CLL14 data are one part of a strategy to shift Venclexta into first-line use in CLL, expanding its market, and also to help consolidate Gazyva’s position in that

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    dominant player, but has been losing market share to ViiV over the last few years. ... They have three trials on the go – FLAIR, ATLAS and ATLAS-2M – with the aim of getting it to market in 2019 or 2020.

  • Bayer preps filings for new prostate cancer drug Bayer preps filings for new prostate cancer drug

    While there are already two rivals on the market, darolutamide’s developers think it has qualities which could make it a good option for patients. ... Non-metastatic CRPC still a largely untapped area, but analysts think that it could develop into a

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    PD-L1 and TKI combination could challenge standard of care. Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new ... Exelixis’ drug could also be threatened by the combination data, although Hsieh

  • HPS Group pushes further into healthcare HPS Group pushes further into healthcare

    In addition, the ability to work with HPS’s in-house capabilities like market research, data analytics, customer insight and motion graphics give us exciting new opportunities to develop

More from news
Approximately 1 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Launch like a PRO: the art and science of successful entry to market Launch like a PRO: the art and science of successful entry to market

    From strategy to project management, market access to public affairs, governance to HEOR, they provide an incredibly thorough test of an organisation’s capability. ... The methodology is simple but powerful. Rigorous desk and customer research into the

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Centralised global or national marketing experts will focus on building core tools, market sizing and comparative metrics. ... They’ll leverage market simulation and testing to develop data-driven messaging and creative packages.

  • Brand teams: why are some smarter than others? Brand teams: why are some smarter than others?

    Compared to your rivals, you and your colleagues have similar backgrounds, use similar methods and work with more or less the same data bought from the same market research companies. ... 3.  Testing, when the hypotheses developed from the explicated

  • Market research

  • Pushing the accelerator Pushing the accelerator

    Improved visibility into data will drive faster and better decision-making across the organisation. ... and market data, or to automatically reallocate manufacturing capacity to avoid product shortages.

More from intelligence
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest appointments

  • Future Thinking appoints Mohamed Muhsin as UK pharma head Future Thinking appoints Mohamed Muhsin as UK pharma head

    Muhsin joins from QuintilesIMS Health, where he was therapy lead, oncology and prior to that he was a senior market analyst at Roche. ... Both Muhsin and Bonrepaux-Caux will be focusing on expanding Future Thinking’s global footprint, technical

  • LaingBuisson names chairman and CEO LaingBuisson names chairman and CEO

    Former Health Secretary Stephen Dorrell and Henry Elphick join. LaingBuisson, a UK healthcare market intelligence provider, has named Stephen Dorrell and Henry Elphick as its chairman and chief executive officer, respectively. ... Elphick said:

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    I look forward to building on the compelling clinical data and initial market access work the PLx management team has begun and to successfully launching PL2200 Aspirin into the U.S. ... market in 2017.” .

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 54 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics